Practical guidelines for multiplicity adjustment in clinical trials.

[1]  J. I.  The Design of Experiments , 1936, Nature.

[2]  D. B. Duncan.  MULTIPLE RANGE AND MULTIPLE F TESTS , 1955 .

[3]  P. O'Brien,et al.  The appropriateness of analysis of variance and multiple-comparison procedures. , 1983, Biometrics.

[4]  O'Brien Pc,et al.  The appropriateness of analysis of variance and multiple-comparison procedures. , 1983 .

[5]  Sarah Parish,et al.  Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. , 1988, Journal of the American College of Cardiology.

[6]  L. Bolognese,et al.  RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2 , 1988, The Lancet.

[7]  A. Tamhane,et al.  Multiple Comparison Procedures , 1989 .

[8]  K J Rothman,et al.  No Adjustments Are Needed for Multiple Comparisons , 1990, Epidemiology.

[9]  Ján,et al.  Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. , 1995, JAMA.

[10]  M. Proschan,et al.  Multiple comparisons with control in a single experiment versus separate experiments : why do we feel differently ? , 1995 .

[11]  R W Makuch,et al.  Can treatment that is helpful on average be harmful to some patients? A study of the conflicting information needs of clinical inquiry and drug regulation. , 1996, Journal of clinical epidemiology.

[12]  Michael A. Proschan,et al.  Rationale and Design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) , 1996 .

[13]  James T. Willerson,et al.  Appointment of New Associate Editor for Circulation , 1996 .

[14]  J. Willerson.  Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. , 1996, Circulation.

[15]  Ji Zhang,et al.  Testing the Hypothesis that Matters for Multiple Primary Endpoints , 1996 .

[16]  Robert L. Frye,et al.  Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. , 1996, The New England journal of medicine.

[17]  L A Moyé,et al.  P-value interpretation and alpha allocation in clinical trials. , 1998, Annals of epidemiology.

[18]  S Hulley,et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.

[19]  H Quan,et al.  Planning and analysis of repeated measures at key time-points in clinical trials sponsored by pharmaceutical companies. , 1999, Statistics in medicine.

[20]  K. Lee,et al.  A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. , 1999, The New England journal of medicine.

[21]  L. Moye.  Alpha calculus in clinical trials: considerations and commentary for the new millennium. , 2000, Statistics in medicine.

[22]  L A Hothorn,et al.  A multiple comparison procedure for three- and four-armed controlled clinical trials. , 2001, Statistics in medicine.